Bimzelx Insurance Denied? How to Appeal Your Bimekizumab Denial

Bimzelx (bimekizumab) is a novel biologic approved for moderate-to-severe plaque psoriasis in adults, and more recently for psoriatic arthritis and ankylosing spondylitis. Uniquely, bimekizumab inhibits both IL-17A and IL-17F — two related cytokines that together drive a significant portion of the inflammatory response in psoriasis and spondyloarthritis. Clinical trials have shown skin clearance rates among the highest achieved by any psoriasis biologic. Despite this strong efficacy profile, insurance denials for Bimzelx are common, particularly given its relatively recent FDA approval (2023). Here's how to appeal.

What Bimzelx Treats and Why Patients Need It

Bimzelx is the first FDA-approved biologic to simultaneously inhibit both IL-17A and IL-17F. Both cytokines contribute to the keratinocyte hyperproliferation and inflammation characteristic of plaque psoriasis. By blocking both, bimekizumab provides more complete pathway inhibition than IL-17A-only inhibitors.

FDA-approved for:

• Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
• Psoriatic arthritis in adults
• Ankylosing spondylitis in adults

In the BE VIVID, BE READY, and BE SURE Phase 3 trials for psoriasis, Bimzelx achieved:

• PASI 90 response in approximately 85% of patients at week 16
• PASI 100 (complete clearance) in approximately 60% of patients
• Sustained responses at 1 year

These clearance rates are among the highest reported for any psoriasis biologic, making Bimzelx a compelling option for patients who require very high-level skin clearance.

Common Denial Reasons for Bimzelx

Step therapy requirements: Insurers typically require failure of topical therapies and at least one systemic agent before approving a biologic. For patients seeking Bimzelx, some plans may also require failure of a TNF inhibitor (Humira, Enbrel) or an IL-17A inhibitor (Cosentyx, Taltz) before approving a dual IL-17A/F inhibitor.

"Newer agent" / insufficient real-world data: Bimzelx received FDA approval in 2023 for psoriasis. Some plans may cite limited long-term real-world data despite robust clinical trial evidence.

Formulary non-coverage or non-preferred tier: Given its recent approval, Bimzelx may not yet be on many formularies, or may be placed on a non-preferred specialty tier.

Preferred IL-17 inhibitor substitution: Plans may direct patients to Cosentyx (secukinumab) or Taltz (ixekizumab) as preferred IL-17 inhibitors rather than covering the newer dual inhibitor.

Step-by-Step: How to Appeal a Bimzelx Denial

Step 1: Get the denial in writing and identify the reason. Is it step therapy, formulary, preferred biologic substitution, or "novel agent" classification?

Step 2: Document your psoriasis treatment history. Include every topical therapy (steroid class, vitamin D analogs, calcineurin inhibitors), phototherapy, and systemic therapy (methotrexate, cyclosporine, acitretin) with dates and outcomes.

Step 3: Document disease severity. PASI score, BSA percentage, DLQI score, and any special body area involvement (face, hands, feet, scalp, nails, genitalia).

Step 4: Have your dermatologist write a Letter of Medical Necessity documenting disease severity, prior treatment failures, and specific rationale for Bimzelx.

Step 5: Challenge "novel agent" denial with Phase 3 trial data. The BE VIVID/READY/SURE trials are published in major journals and the FDA evaluated these data in granting approval. This is not an experimental drug.

Step 6: If required to try a different IL-17 inhibitor first, either document failure of those agents or have your doctor explain why Bimzelx's dual IL-17A/F mechanism is specifically clinically superior for your case.

Step 7: File internal appeal and request peer-to-peer review.

Step 8: File external appeal if needed.

What to Include in Your Bimzelx Appeal Letter

• Policy number, member ID, and claim reference
• Bimekizumab (Bimzelx) prescribed dose and indication
• Current PASI score, BSA, and DLQI
• Prior treatment history: topicals, phototherapy, systemics, prior biologics
• Letter of Medical Necessity from dermatologist
• FDA approval date (October 2023 for psoriasis) and phase 3 trial citations
• BE VIVID, BE READY, and BE SURE trial clearance rate data
• Response to any "experimental" claims with regulatory approval documentation
• Request for peer-to-peer review

Success Tips for Bimzelx Appeals

Lead with the efficacy data. PASI 100 rates of approximately 60% at 16 weeks are extraordinary — among the highest ever achieved in a psoriasis trial. If near-complete clearance is your clinical goal (for instance, due to professional appearance requirements, psychological impact, or special site involvement), these trial results support the specific choice of bimekizumab.

Challenge "experimental" classification with FDA approval. Any plan denying Bimzelx as "experimental" or "investigational" after FDA approval in 2023 is factually wrong. Cite the FDA approval and the Phase 3 data that supported it.

Document the dual mechanism advantage. If you had only partial response to an IL-17A inhibitor like Cosentyx, this can support the argument that dual IL-17A/F inhibition addresses a pathway element that prior therapy missed.

Emphasize quality of life impact. Severe psoriasis is psychologically devastating — depression, anxiety, and social isolation are well-documented. The DLQI and validated quality-of-life instruments capture this in a way insurers recognize.

Fight Back With ClaimBack

Bimzelx represents one of the most effective psoriasis treatments ever developed. If your insurer denied this medication, ClaimBack can help you fight back with a well-organized, evidence-based appeal.

Start your Bimzelx appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied